Nangibotide - Inotrem

Drug Profile

Nangibotide - Inotrem

Alternative Names: CardioTREM; LR-12; Motrem

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inotrem
  • Class Peptides
  • Mechanism of Action Immunomodulators; TREML1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Septic shock
  • Phase I Myocardial infarction

Most Recent Events

  • 17 Jul 2018 Phase-I clinical trials in Myocardial infarction in France (IV), before July 2018 (Inotrem pipeline, July 2018)
  • 13 Jun 2018 Inotrem completes a phase II trial in Septic shock in France, Belgium, Netherlands, Spain (IV) (NCT03158948) (EudraCT2016-005032-14)
  • 15 Nov 2017 LR 12 receives Priority Medicine (PRIME) status for Septic shock in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top